Stem Cell-Derived Retina Cells Show Sustained Vision Gains Three Years After a Single Treatment for Geographic Atrophy

What This Article Covers

Three-year follow-up data from a small, ongoing Phase 1/2a trial of OpRegen (RG6501), a stem cell-derived retinal pigment epithelium (RPE) cell therapy being developed by Lineage Cell Therapeutics in partnership with Genentech, a member of the Roche Group, show that a single subretinal injection was associated with sustained gains in visual acuity and, on imaging, apparent partial structural recovery in patients with geographic atrophy (GA), the advanced, currently untreatable form of dry age-related macular degeneration (AMD) that normally only worsens over time. The data were presented in 2026 and reaffirmed in the company's most recent quarterly business update; a larger Phase 2a study designed to refine delivery of the therapy is now actively enrolling at 17 sites in the United States and Israel.

What Happened

On May 4, 2026, Lineage Cell Therapeutics announced that three-year results from its Phase 1/2a study of OpRegen had been presented by Eyal Banin, M.D., Ph.D., of the Center for Retinal and Macular Degenerations at Hadassah-Hebrew University Medical Center, at the Foundation Fighting Blindness' Retinal Innovation Summit 2026. The company reaffirmed the findings and provided an updated trial status in its second-quarter 2026 financial results, released August 7, 2026, confirming that the underlying Phase 1/2a study (NCT02286089) continues to generate long-term follow-up data and that a newer, related study, the "GAlette" trial (NCT05626114), remains open and actively recruiting.

OpRegen is a suspension of allogeneic RPE cells, derived from human pluripotent stem cells, delivered via a single subretinal injection. The RPE is a layer of cells beneath the retina's photoreceptors that is essential to their survival; in geographic atrophy, patches of RPE and overlying photoreceptors progressively die off, causing irreversible blind spots that expand over time. There is no FDA-approved treatment that restores vision already lost to GA, and current approved therapies for the condition (complement inhibitors) are aimed only at slowing the rate of lesion growth, not improving sight.

What the Data Actually Show

The Phase 1/2a study enrolled 24 patients across four dose-escalation cohorts. The first three cohorts consisted of patients who were already legally blind in the study eye (best-corrected visual acuity, or BCVA, of 20/200 or worse); Cohort 4 enrolled 12 patients with more residual vision (BCVA between 20/65 and 20/250), allowing for a more sensitive assessment of visual benefit.

In Cohort 4, patients evaluable at 36 months (n=10) showed a mean improvement of +6.2 ETDRS letters from baseline, up slightly from +5.5 letters at the 24-month mark — meaning the benefit was not only present but had not faded with time, three years after a single administration. Among the five patients whose treated area achieved the most extensive coverage by the transplanted cells, the effect was larger still: a mean gain of +9.0 ETDRS letters at 36 months, up from +7.4 letters at 24 months. For context, a gain of roughly 5 letters is generally considered a clinically meaningful change in vision trials.

Optical coherence tomography imaging added a structural dimension to the finding. In the five patients with extensive cell coverage, the treated eye's RPE-complex area increased by 1.9 mm² over 36 months, while the untreated fellow eye lost 3.8 mm² over the same period. A similar divergence was seen in the external limiting membrane, a marker associated with photoreceptor integrity: +0.3 mm² in treated eyes versus −3.4 mm² in untreated fellow eyes. Lineage and its investigators describe this as evidence of a reappearing RPE layer and features "associated with recovery of photoreceptors" — a signal, they say, that the transplanted cells may be counteracting the underlying degenerative process rather than merely slowing it.

Context and Limitations

These results are genuinely notable because geographic atrophy is, by definition, a one-way disease under current standards of care: affected retinal area only grows, and vision, once lost, does not return. A signal of stabilization or improvement — even in a handful of patients — runs counter to the expected natural history and is why retinal specialists have paid close attention to this program since earlier data readouts.

That said, the caveats are substantial and should not be minimized. This is an open-label, single-arm, dose-escalation Phase 1/2a study — its primary purpose was to establish safety and tolerability, not efficacy, and it has no randomized, sham-treated control group; the "untreated fellow eye" comparisons, while informative, are not a substitute for a randomized trial. The most encouraging visual-acuity numbers come from a subgroup of just five patients who happened to achieve the most extensive cell coverage, not the full cohort, and Cohort 4 itself numbered only 12 patients to begin with. Earlier safety follow-up from this same trial (reported in 2021, with a larger patient set across all four cohorts) found that all 24 enrolled patients experienced at least one adverse event, though 87% of reported events were mild, and investigators found no unexpected or serious treatment-related adverse events, no acute or delayed intraocular inflammation, and no sustained rise in intraocular pressure — reassuring for a surgical, cell-based intervention, but not a guarantee that a larger population would fare identically. OpRegen is not FDA-approved, is not available outside of clinical trials, and could still be years from a regulatory filing.

What Comes Next

The newer GAlette study is a Phase 2a trial specifically designed to optimize subretinal surgical delivery of OpRegen, evaluating proprietary delivery devices that Genentech believes may offer advantages over the instruments used in earlier cohorts — an acknowledgment by the sponsors themselves that how consistently the cells are delivered to the retina appears to matter for how much benefit patients see. As of the August 2026 update, that trial was open and enrolling at 17 sites in the U.S. and Israel, with no completion date yet disclosed. Investors and analysts will be watching whether more consistent, higher-coverage delivery in this larger study reproduces the visual and structural gains seen in the most favorably treated patients from the earlier trial.

What It Means for Patients

For the roughly hundreds of thousands of people living with geographic atrophy in the U.S. alone, today's approved options only slow lesion growth; none restore sight. These early data raise a real, if still preliminary, possibility that a regenerative cell-based approach could eventually do more than that. Patients and caregivers should treat this as encouraging early-stage science, not an available treatment: OpRegen remains investigational, the strongest results come from a small subgroup within a small trial, and a properly controlled, larger study is still needed before any conclusions about real-world efficacy can be drawn. Anyone interested in eligibility for ongoing OpRegen studies should discuss options with their retina specialist and consult the official ClinicalTrials.gov listings directly.

Bottom Line

Three-year data from an early-stage, 24-patient trial suggest that a single injection of stem cell-derived retinal pigment epithelium cells may produce durable, and in some patients growing, improvements in vision and retinal structure in geographic atrophy — a disease that otherwise only worsens. The signal is real and scientifically important, but it comes from an uncontrolled Phase 1/2a study with small subgroups, and a larger Phase 2a trial now underway will be the real test of whether this benefit holds up at scale before OpRegen could ever become an approved therapy.